SPECTRUM PHARMACEUTICALS INC: insider trades · United States · SEC (Form 4)

About SPECTRUM PHARMACEUTICALS INC

Spectrum Pharmaceuticals Inc. is a U.S. biopharmaceutical company that was historically focused on targeted oncology and hematology-oncology therapies. Founded in 1987, the company changed its corporate name to Spectrum Pharmaceuticals, Inc. in 2002. Its shares were listed on the U.S. market, specifically Nasdaq under the ticker SPPI, making it a classic small-cap biotech name for investors seeking exposure to clinical, regulatory, and commercialization execution rather than a diversified pharmaceutical platform. ([sec.gov](https://www.sec.gov/Archives/edgar/data/831547/000083154723000007/sppi-20221231.htm)) Over time, Spectrum underwent a major portfolio reset. In March 2019, it sold its then-commercial portfolio of seven marketed drugs, which marked a strategic shift away from legacy assets and toward a narrower, more specialized oncology strategy. In its later SEC filings, the company described itself as a commercial-stage biopharmaceutical business pursuing the acquisition, development, and commercialization of novel and targeted cancer therapies. This repositioning is important for investors because it shows Spectrum was trying to transform from a legacy product company into a more focused, higher-risk growth story. ([sec.gov](https://www.sec.gov/Archives/edgar/data/831547/000083154723000007/sppi-20221231.htm)) Before its acquisition, the company’s core commercial asset was ROLVEDON, a long-acting G-CSF used to reduce the incidence of febrile neutropenia in adult patients receiving cancer treatment. Spectrum also advanced poziotinib, an irreversible tyrosine kinase inhibitor being studied in non-small cell lung cancer with HER2 exon 20 insertion mutations. However, the program ran into a major regulatory setback: after an unfavorable FDA advisory committee vote, Spectrum received a Complete Response Letter from the FDA, and the company later de-prioritized further development efforts. That sequence underscores how dependent small oncology biotech companies are on binary FDA outcomes. ([sec.gov](https://www.sec.gov/Archives/edgar/data/831547/000083154723000007/sppi-20221231.htm)) Competitive positioning was modest but clear: Spectrum operated in a crowded oncology market against large pharmaceutical companies and other biotech peers, relying on differentiation of its assets, a focused sales force, and selective business development. The company also disclosed meaningful dependence on third-party manufacturers and a limited number of distributors, which added operational and supply-chain risk to the investment case. For equity analysts, those disclosures are a reminder that commercial potential in biotech can be constrained by manufacturing concentration, regulatory timing, and payer/reimbursement execution. ([sec.gov](https://www.sec.gov/Archives/edgar/data/831547/000083154723000007/sppi-20221231.htm)) The most important recent event is that Spectrum Pharmaceuticals was acquired by Assertio Holdings on July 31, 2023. In that transaction, each Spectrum share was exchanged for Assertio shares plus a contingent value right tied to future ROLVEDON sales milestones. As a result, SPPI’s standalone public-equity story effectively ended after the deal closed. For French, Belgian, and Swiss investors, Spectrum is best viewed today as a former Nasdaq-listed United States oncology biotech whose value was ultimately absorbed into a broader specialty-pharma platform. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1808665/000180866524000012/asrt-20231231.htm?utm_source=openai))